Sorafenib in Treating Patients With Recurrent or Progressive Malignant Glioma

PHASE1CompletedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

December 31, 2004

Primary Completion Date

October 31, 2010

Study Completion Date

December 31, 2011

Conditions
Adult Anaplastic AstrocytomaAdult Anaplastic OligodendrogliomaAdult Giant Cell GlioblastomaAdult GliosarcomaRecurrent Adult Brain Tumor
Interventions
DRUG

sorafenib tosylate

Given PO

OTHER

pharmacological study

Correlative studies

Trial Locations (10)

19104

University of Pennsylvania/Abramson Cancer Center, Philadelphia

21287

Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore

27157

Wake Forest University Health Sciences, Winston-Salem

30322

Emory University/Winship Cancer Institute, Atlanta

33612

H. Lee Moffitt Cancer Center and Research Institute, Tampa

35294

University of Alabama at Birmingham, Birmingham

44195

Cleveland Clinic Foundation, Cleveland

48202

Henry Ford Hospital, Detroit

21231-1000

Adult Brain Tumor Consortium, Baltimore

02114

Massachusetts General Hospital Cancer Center, Boston

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00093613 - Sorafenib in Treating Patients With Recurrent or Progressive Malignant Glioma | Biotech Hunter | Biotech Hunter